1、Table of ContentsAs filed with the U.S.Securities and Exchange Commission on June 24,2025.Registration No.333-UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM S-1REGISTRATION STATEMENTUNDER THE SECURITIES ACT OF 1933Liminatus Pharma,Inc.(Exact name of registrant as specified i

2、n its charter)Delaware 6770 93-2710748(State or other jurisdiction ofincorporation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification No.)6 Centerpointe Drive#625La Palma,California 90623Tel:(213)273-5453(Address,including zip code,and telephone numb

3、er,including area code,of registrants principal executive offices)Chris Kim6 Centerpointe Drive#625La Palma,California 90623Tel:(213)273-5453(Name,address,including zip code,and telephone number,including area code,of agent for service)Copies to:Mitchell S.NussbaumGiovanni CarusoLoeb&Loeb LLP345 Par

4、k AvenueNew York,NY 10154Telephone:(212)407-4000Approximate date of commencement of proposed sale to public:From time to time after the effective date hereof.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under theSecuri

5、ties Act of 1933 check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the followingbox and list the Securities Act registration statement number of the earlier effective registration statement for

6、 the same offering.If this Form is a post-effective amendment filed pursuant to Rule 462(c)under the Securities Act,check the following box and list the SecuritiesAct registration statement number of the earlier effective registration statement for the same offering.If this Form is a post-effective